Herantis Pharma Secures FDA Green Light, Funding for HER‑096 Phase 2a Parkinson Trial
Herantis Pharma’s FDA‑approved Phase 2a design for HER‑096 accelerates Parkinson’s trials, with 50%+ funding secured and a 100‑patient study poised to launch in the U.S.
3 minutes to read